How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

VI

NASDAQ:VIRX
Get a brief AI stock analysisSaves ~ 15 minutes of your time

VI

Viracta Therapeutics IncNASDAQ VIRX Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is VIRX undervalued compared to its fair value?

The fair value of VIRX stock is hidden USD. Relative to the market price of 0.547 USD Viracta Therapeutics Inc is hidden.

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, ...[More about valuation]

Viracta Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.022 $B

Price:

0.547 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.355

FINANCIALS

Viracta Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.014 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.014 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.057 B
0.018 B

Financial Position Analysis

Assets

0.057 B
Current Assets
0.055 B
Total non-current assets
0.0017 B

Total current liabilities
0.038 B
Total non-current liabilities

Cash Flow Statement

-0.01 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.01 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Viracta Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is VIRX attractive for investment based on fundamental analysis?

VIRX stock rating is hidden. Viracta Therapeutics is a hidden by Eyestock methodology.

Get VIRX Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

Debt / Equity ratio:

ROE:

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

VIRX analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for VIRX to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Viracta Therapeutics Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Viracta Therapeutics Inc dividends

VIRX dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About VIRX stock

About the company Viracta Therapeutics Inc

Market cap $B

0.022

Dividend yield

Shares outstanding

38.4109 B

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 32 full-time employees. The company went IPO on 2005-09-27. The firm is focused on advancing new medicines for the treatment of virus-associated malignancies. The firm conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including Phase II basket trial for the treatment of multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1), as well as a Phase Ib/II trial for the treatment of EBV+ recurrent and other EBV+ solid tumors. The firm's product candidate pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor.

VIRX profile

  • Ticker

    VIRX

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    27 September 2005

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    32

  • City

    Cardiff-by-the-Sea

  • Address

    2533 S Coast Hwy 101, Suite 210

  • Cusip

    92765F108